198 related articles for article (PubMed ID: 37105842)
1. Direct-acting oral anticoagulants in antiphospholipid syndrome: A systematic review.
Girón-Ortega JA; Girón-González JA
Med Clin (Barc); 2023 Jul; 161(2):65-77. PubMed ID: 37105842
[TBL] [Abstract][Full Text] [Related]
2. Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome.
Bala MM; Celinska-Lowenhoff M; Szot W; Padjas A; Kaczmarczyk M; Swierz MJ; Undas A
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD012169. PubMed ID: 28968483
[TBL] [Abstract][Full Text] [Related]
3. Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome.
Bala MM; Celinska-Lowenhoff M; Szot W; Padjas A; Kaczmarczyk M; Swierz MJ; Undas A
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012169. PubMed ID: 33045766
[TBL] [Abstract][Full Text] [Related]
4. Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature.
Dufrost V; Risse J; Zuily S; Wahl D
Curr Rheumatol Rep; 2016 Dec; 18(12):74. PubMed ID: 27812956
[TBL] [Abstract][Full Text] [Related]
5. Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis.
Dufrost V; Risse J; Reshetnyak T; Satybaldyeva M; Du Y; Yan XX; Salta S; Gerotziafas G; Jing ZC; Elalamy I; Wahl D; Zuily S
Autoimmun Rev; 2018 Oct; 17(10):1011-1021. PubMed ID: 30103045
[TBL] [Abstract][Full Text] [Related]
6. Direct oral anticoagulants in antiphospholipid syndrome: Meta-analysis of randomized controlled trials.
Dufrost V; Wahl D; Zuily S
Autoimmun Rev; 2021 Jan; 20(1):102711. PubMed ID: 33197580
[TBL] [Abstract][Full Text] [Related]
7. Therapy with direct oral anticoagulants for secondary prevention of thromboembolic events in the antiphospholipid syndrome: a systematic review and meta-analysis of randomised trials.
Adelhelm JBH; Christensen R; Balbi GGM; Voss A
Lupus Sci Med; 2023 Oct; 10(2):. PubMed ID: 37899090
[TBL] [Abstract][Full Text] [Related]
8. Comparing the efficacy and safety of direct oral anticoagulants versus Vitamin K antagonists in patients with antiphospholipid syndrome: a systematic review and meta-analysis.
Wu X; Cao S; Yu B; He T
Blood Coagul Fibrinolysis; 2022 Oct; 33(7):389-401. PubMed ID: 35867933
[TBL] [Abstract][Full Text] [Related]
9. Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome: A Randomized Noninferiority Trial.
Ordi-Ros J; Sáez-Comet L; Pérez-Conesa M; Vidal X; Riera-Mestre A; Castro-Salomó A; Cuquet-Pedragosa J; Ortiz-Santamaria V; Mauri-Plana M; Solé C; Cortés-Hernández J
Ann Intern Med; 2019 Nov; 171(10):685-694. PubMed ID: 31610549
[TBL] [Abstract][Full Text] [Related]
10. Direct oral anticoagulants versus warfarin in patients with antiphospholipid syndrome: A meta-analysis of randomized controlled trials.
Lee YH; Song GG
Lupus; 2022 Oct; 31(11):1335-1343. PubMed ID: 35968627
[TBL] [Abstract][Full Text] [Related]
11. Use of direct oral anticoagulants in antiphospholipid syndrome.
Cohen H; Efthymiou M; Isenberg DA
J Thromb Haemost; 2018 Jun; 16(6):1028-1039. PubMed ID: 29624847
[TBL] [Abstract][Full Text] [Related]
12. Direct oral anticoagulants versus warfarin in patients with single or double antibody-positive antiphospholipid syndrome.
Williams B; Saseen JJ; Trujillo T; Palkimas S
J Thromb Thrombolysis; 2022 Jul; 54(1):67-73. PubMed ID: 34817786
[TBL] [Abstract][Full Text] [Related]
13. Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE.
Cohen H; Doré CJ; Clawson S; Hunt BJ; Isenberg D; Khamashta M; Muirhead N;
Lupus; 2015 Sep; 24(10):1087-94. PubMed ID: 25940537
[TBL] [Abstract][Full Text] [Related]
14. Recurrent Thrombosis With Direct Oral Anticoagulants in Antiphospholipid Syndrome: A Systematic Literature Review and Meta-analysis.
Sanchez-Redondo J; Espinosa G; Varillas Delgado D; Cervera R
Clin Ther; 2019 Sep; 41(9):1839-1862. PubMed ID: 31405527
[TBL] [Abstract][Full Text] [Related]
15. Comparing APLS and oranges: caution with the use of direct-acting oral anticoagulants (DOACs) instead of warfarin in the treatment of antiphospholipid syndrome (APLS).
Benger M; Vink J; Snell LB; Breen K
BMJ Case Rep; 2019 Apr; 12(4):. PubMed ID: 30940667
[TBL] [Abstract][Full Text] [Related]
16. Direct oral anticoagulants in antiphospholipid syndrome: a real life case series.
Betancur JF; Bonilla-Abadía F; Hormaza AA; Jaramillo FJ; Cañas CA; Tobón GJ
Lupus; 2016 May; 25(6):658-62. PubMed ID: 26743321
[TBL] [Abstract][Full Text] [Related]
17. New Insights into the Use of Direct Oral Anticoagulants in Non-high Risk Thrombotic APS Patients: Literature Review and Subgroup Analysis from a Meta-analysis.
Dufrost V; Darnige L; Reshetnyak T; Vorobyeva M; Jiang X; Yan XX; Gerotziafas G; Jing ZC; Elalamy I; Wahl D; Zuily S
Curr Rheumatol Rep; 2020 May; 22(7):25. PubMed ID: 32436109
[TBL] [Abstract][Full Text] [Related]
18. The use of direct oral anticoagulants in 56 patients with antiphospholipid syndrome.
Malec K; Góralczyk T; Undas A
Thromb Res; 2017 Apr; 152():93-97. PubMed ID: 27989533
[TBL] [Abstract][Full Text] [Related]
19. Treatment of the antiphospholipid syndrome with direct oral anticoagulantsPosition statement of German societies.
Bauersachs R; Langer F; Kalka C; Konstantinides S; Klamroth R; Oldenburg J; Schellong S; Scholz U; Stücker M; Lindhoff-Last E
Vasa; 2019 Nov; 48(6):483-486. PubMed ID: 31621546
[No Abstract] [Full Text] [Related]
20. After failure with acenocoumarol, rivaroxaban in antiphospholipid syndrome: A report of 2 cases.
Mateos Rodríguez JJ; Bellido D; Castro D; Portillo Sánchez J; Vanegas R; Núñez García A
Reumatol Clin (Engl Ed); 2019; 15(5):e33-e35. PubMed ID: 28546102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
